GT Biopharma, Inc.
GTBP
Last
$6.68
Day
+12.1%
1y
-68.3%
5y
-99.9%
52w
-79.3%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1334d
EMA 21
6.68
EMA 50
7.36
EMA 200
13.20
20d high
-50.3%
5y high
-99.9%
5y range
0th
Positions held
Your positionsGTBP isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$6.84
Stop
$5.23
Stop distance
21.7%
Target vs last
+2.4%
Fundamentals
| Market cap | $10.75M | Enterprise value | $5.80M | Trailing P/E | — | Forward P/E | -0.55 |
| PEG | 1.05 | Price / book | 2.98 | Beta | 0.86 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -113.5% | ROA | -1.6% | Debt / equity | — |
| Current ratio | 2.61 | Free cash flow | -$8.87M | Analyst recommendation | none | Mean target | $75.00 |
| 52w high | $28.75 | 52w low | $4.91 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | — | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — | — |
| Net income | — | -$2.8M | -$23.0M | $8.3M | -$30.2M | -$0.8M |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | -$2.8M | -$5.6M | -$3.4M | -$1.5M | -$1.9M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$28.4M | -$13.2M | -$7.6M | -$20.9M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$12.4M | -$14.4M | -$13.6M | -$21.3M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
Price (daily)
Full chart · RSI · MACD · patternsGTBP · daily-17.0% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin